Liquidia Reports $148.3M in YUTREPIA Sales for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy LQDA?
Source: Globenewswire
- Strong Sales Performance: Liquidia achieved approximately $90.1 million in net product sales for YUTREPIA in Q4 2025, totaling $148.3 million for the full year, reflecting a robust 74% quarter-over-quarter growth that underscores strong market demand and the company's execution capabilities.
- Positive Cash Flow: The company generated over $30 million in positive cash flow during Q4 2025, which not only enhances financial stability but also provides funding for future R&D and market expansion initiatives.
- Significant Prescription Growth: Since its launch in June 2025, YUTREPIA has received more than 2,800 unique patient prescriptions, with over 2,200 patients treated and an 85% conversion rate from prescription to treatment, indicating growing physician confidence and market acceptance.
- Future Development Plans: Liquidia plans to continue investing in clinical development in 2026 to advance YUTREPIA and L606, addressing unmet medical needs and further solidifying its market position in treating pulmonary arterial hypertension and related diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.780
Low
31.00
Averages
47.50
High
67.00
Current: 31.780
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Set to Announce FY Earnings on March 5
- Earnings Announcement: Liquidia (LQDA) is set to announce its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.62, reflecting a 62.7% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Surge Expected: The revenue estimate stands at $153.82 million, representing a staggering 999.5% year-over-year increase, which highlights significant growth in market share and product sales, likely boosting investor confidence moving forward.
- Performance Review: Over the past year, Liquidia has not met EPS estimates at all, while it has only met revenue estimates 25% of the time, suggesting a need for improvement in profitability despite a relatively strong revenue performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward and two downward revisions, while revenue estimates experienced four upward and two downward revisions, indicating analyst divergence and uncertainty regarding Liquidia's future performance.
See More
Opaleye Management Sells Liquidia Shares Worth $5.12 Million
- Share Sale Details: Opaleye Management disclosed in an SEC filing on February 17, 2026, that it sold 180,000 shares of Liquidia, valued at approximately $5.12 million, indicating a strategic reduction in its holdings.
- Holding Proportion Change: Following this transaction, Opaleye's stake in Liquidia decreased to 2.435 million shares, representing 11.21% of its reportable AUM, reflecting a cautious outlook on the company's future performance.
- Market Performance Analysis: As of February 17, 2026, Liquidia's stock was priced at $33.84, marking a 105.7% increase over the past year, significantly outperforming the S&P 500 by 97 percentage points, showcasing its strong growth potential in the biopharmaceutical sector.
- Company Overview: Liquidia focuses on innovative therapies for pulmonary arterial hypertension, primarily generating revenue through the development and commercialization of proprietary and generic therapies, demonstrating its competitive advantage in a highly regulated pharmaceutical industry.
See More
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge Nearly 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to drive further revenue growth for the company.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, enhancing financial stability and providing support for future investments.
- Future Development Plans: Liquidia aims to strengthen clinical programs for both Yutrepia and its leading investigational drug L606, focusing on differentiating these pulmonary arterial hypertension treatments to expand market share and enhance competitiveness.
- Significant Market Potential: The rapid market progress of Yutrepia suggests it could become a go-to medication for pulmonary arterial hypertension and related conditions, further solidifying Liquidia's position in the biopharmaceutical sector.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for its latest product Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to further drive revenue growth.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, providing financial support for future R&D and market expansion.
- Optimistic Market Outlook: Since its FDA approval, Yutrepia has received positive market feedback, with early indications suggesting it could become a go-to medication for pulmonary arterial hypertension and related conditions, thereby strengthening Liquidia's competitive position in the biopharmaceutical sector.
- Clear Future Plans: Liquidia aims to enhance clinical programs for both Yutrepia and its leading investigational drug L606 to further differentiate their offerings and expand potential indications, demonstrating the company's strategic focus on future growth opportunities.
See More
Liquidia Set to Announce FY Earnings on March 5
- Earnings Announcement: Liquidia (LQDA) is set to announce its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.62, reflecting a 62.7% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Surge Expected: The revenue estimate stands at $153.82 million, representing a staggering 999.5% year-over-year increase, which highlights significant growth in market share and product sales, likely boosting investor confidence moving forward.
- Performance Review: Over the past year, Liquidia has not met EPS estimates at all, while it has only met revenue estimates 25% of the time, suggesting a need for improvement in profitability despite a relatively strong revenue performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward and two downward revisions, while revenue estimates experienced four upward and two downward revisions, indicating analyst divergence and uncertainty regarding Liquidia's future performance.
See More
Opaleye Management Sells Liquidia Shares Worth $5.12 Million
- Share Sale Details: Opaleye Management disclosed in an SEC filing on February 17, 2026, that it sold 180,000 shares of Liquidia, valued at approximately $5.12 million, indicating a strategic reduction in its holdings.
- Holding Proportion Change: Following this transaction, Opaleye's stake in Liquidia decreased to 2.435 million shares, representing 11.21% of its reportable AUM, reflecting a cautious outlook on the company's future performance.
- Market Performance Analysis: As of February 17, 2026, Liquidia's stock was priced at $33.84, marking a 105.7% increase over the past year, significantly outperforming the S&P 500 by 97 percentage points, showcasing its strong growth potential in the biopharmaceutical sector.
- Company Overview: Liquidia focuses on innovative therapies for pulmonary arterial hypertension, primarily generating revenue through the development and commercialization of proprietary and generic therapies, demonstrating its competitive advantage in a highly regulated pharmaceutical industry.
See More
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge Nearly 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to drive further revenue growth for the company.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, enhancing financial stability and providing support for future investments.
- Future Development Plans: Liquidia aims to strengthen clinical programs for both Yutrepia and its leading investigational drug L606, focusing on differentiating these pulmonary arterial hypertension treatments to expand market share and enhance competitiveness.
- Significant Market Potential: The rapid market progress of Yutrepia suggests it could become a go-to medication for pulmonary arterial hypertension and related conditions, further solidifying Liquidia's position in the biopharmaceutical sector.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for its latest product Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to further drive revenue growth.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, providing financial support for future R&D and market expansion.
- Optimistic Market Outlook: Since its FDA approval, Yutrepia has received positive market feedback, with early indications suggesting it could become a go-to medication for pulmonary arterial hypertension and related conditions, thereby strengthening Liquidia's competitive position in the biopharmaceutical sector.
- Clear Future Plans: Liquidia aims to enhance clinical programs for both Yutrepia and its leading investigational drug L606 to further differentiate their offerings and expand potential indications, demonstrating the company's strategic focus on future growth opportunities.
See More
